Steven Girgenti - Aug 29, 2022 Form 3 Insider Report for bioAffinity Technologies, Inc. (BIAF)

Signature
/s/ Wilhelm E. Liebmann, as attorney-in-fact for Steven Girgenti
Stock symbol
BIAF
Transactions as of
Aug 29, 2022
Transactions value $
$0
Form type
3
Date filed
11/8/2022, 05:05 AM
Next filing
Nov 8, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BIAF Common Stock, par value $0.007 249K Aug 29, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BIAF Secured Convertible Promissory Note Aug 29, 2022 Common Stock 7.66K $4.20 By Trust F1, F2, F3
holding BIAF Secured Convertible Promissory Note Aug 29, 2022 Common Stock 157K $4.20 Direct F1, F4
holding BIAF Secured Convertible Promissory Note Aug 29, 2022 Common Stock 7.66K $4.20 Direct F1, F5
holding BIAF Secured Convertible Promissory Note Aug 29, 2022 Common Stock 59.1K $4.20 Direct F1, F6
holding BIAF Secured Convertible Promissory Note Aug 29, 2022 Common Stock 58.8K $4.20 Direct F1, F7
holding BIAF Unsecured Convertible Promissory Note Aug 29, 2022 Common Stock 27.4K $4.20 Direct F1, F8
holding BIAF Unsecured Convertible Promissory Note Aug 29, 2022 Common Stock 4.91K $4.20 Direct F1, F9
holding BIAF Unsecured Convertible Promissory Note Aug 29, 2022 Common Stock 2.69K $4.20 Direct F1, F10
holding BIAF Unsecured Convertible Promissory Note Aug 29, 2022 Common Stock 13.3K $4.20 Direct F1, F11
holding BIAF Unsecured Convertible Promissory Note Aug 29, 2022 Common Stock 10.6K $4.20 Direct F1, F12
holding BIAF Unsecured Convertible Promissory Note Aug 29, 2022 Common Stock 39.3K $4.20 Direct F1, F13
holding BIAF Unsecured Convertible Promissory Note Aug 29, 2022 Common Stock 15.6K $4.20 Direct F1, F14
holding BIAF Unsecured Convertible Promissory Note Aug 29, 2022 Common Stock 35.9K $4.20 Direct F1, F15
holding BIAF Warrants (right to buy) Aug 29, 2022 Common Stock 124K $5.25 Direct F1, F16
holding BIAF Warrants (right to buy) Aug 29, 2022 Common Stock 2.38K $5.25 By Trust F1, F2
holding BIAF Series A Convertible Preferred Stock Aug 29, 2022 Common Stock 139K $3.60 Direct F1, F17
holding BIAF Series A Convertible Preferred Stock Aug 29, 2022 Common Stock 1.3K $7.70 By Trust F1, F2, F17
holding BIAF Stock Option (right to buy) Aug 29, 2022 Common Stock 64.8K $1.16 Direct F1, F18
holding BIAF Stock Option (right to buy) Aug 29, 2022 Common Stock 3.57K $4.20 Direct F1, F19
holding BIAF Stock Option (right to buy) Aug 29, 2022 Common Stock 3.57K $7.00 Direct F1, F20
holding BIAF Stock Option (right to buy) Aug 29, 2022 Common Stock 3.57K $7.00 Direct F1, F21
holding BIAF Stock Option (right to buy) Aug 29, 2022 Common Stock 7.14K $7.70 Direct F1, F22
holding BIAF Stock Option (right to buy) Aug 29, 2022 Common Stock 7.14K $7.70 Direct F1, F23
holding BIAF Stock Option (right to buy) Aug 29, 2022 Common Stock 7.14K $7.70 Direct F1, F24
holding BIAF Stock Option (right to buy) Aug 29, 2022 Common Stock 7.14K $4.20 Direct F1, F25
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of securities and exercise prices reported in this Form 3 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO").
F2 These securities are owned directly by the Cranye Girgenti Testamentary Trust (the "Trust") and indirectly by Mr. Girgenti as trustee of the Trust. Mr. Girgenti disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F3 Represents $32,161.64 of outstanding principal and accrued and unpaid interest of this secured Note, dated February 7, 2019 calculated through September 6, 2022, on which date it is expected that this amount will automatically convert into 7,657 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis) in connection with the closing of the IPO.
F4 Represents $657,731.96 of outstanding principal and accrued and unpaid interest of this secured convertible promissory note (a "Note"), dated December 21, 2018 calculated through September 6, 2022, on which date it is expected that this amount will automatically convert into 156,602 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis) in connection with the closing of the IPO.
F5 Represents $32,161.64 of outstanding principal and accrued and unpaid interest of this secured Note, dated February 7, 2019 calculated through September 6, 2022, on which date it is expected that this amount will automatically convert into 7,657 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis) in connection with the closing of the IPO.
F6 Represents $248,394.52 of outstanding principal and accrued and unpaid interest of this secured Note, dated August 29, 2019 calculated through September 6, 2022, on which date it is expected that this amount will automatically convert into 59,141 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis) in connection with the closing of the IPO.
F7 Represents $246,947.95 of outstanding principal and accrued and unpaid interest of this secured Note, dated October 1, 2019 calculated through September 6, 2022, on which date it is expected that this amount will automatically convert into 58,797 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis) in connection with the closing of the IPO.
F8 Represents $114,991.78 of outstanding principal and accrued and unpaid interest of this unsecured Note, dated October 22, 2020 calculated through September 6, 2022, on which date it is expected that this amount will automatically convert into 27,378 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis) in connection with the closing of the IPO.
F9 Represents $20,633.60 of outstanding principal and accrued and unpaid interest of this unsecured Note, dated October 26, 2020 calculated through September 6, 2022, on which date it is expected that this amount will automatically convert into 4,912 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis) in connection with the closing of the IPO.
F10 Represents $11,317.26 of outstanding principal and accrued and unpaid interest of this unsecured Note, dated January 13, 2021 calculated through September 6, 2022, on which date it is expected that this amount will automatically convert into 2,694 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis) in connection with the closing of the IPO.
F11 Represents $55,972.60 of outstanding principal and accrued and unpaid interest of this unsecured Note, dated March 10, 2021 calculated through September 6, 2022, on which date it is expected that this amount will automatically convert into 13,326 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis) in connection with the closing of the IPO.
F12 Represents $44,655.34 of outstanding principal and accrued and unpaid interest of this unsecured Note, dated March 24, 2021 calculated through September 6, 2022, on which date it is expected that this amount will automatically convert into 10,632 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis) in connection with the closing of the IPO.
F13 Represents $164,958.90 of outstanding principal and accrued and unpaid interest of this unsecured Note, dated June 8, 2021 calculated through September 6, 2022, on which date it is expected that this amount will automatically convert into 39,275 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis) in connection with the closing of the IPO.
F14 Represents $65,654.79 of outstanding principal and accrued and unpaid interest of this unsecured Note, dated July 3, 2021 calculated through September 6, 2022, on which date it is expected that this amount will automatically convert into 15,632 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis) in connection with the closing of the IPO.
F15 Represents $150,641.10 of outstanding principal and accrued and unpaid interest of this unsecured Note, dated August 11, 2022 calculated through September 6, 2022, on which date it is expected that this amount will automatically convert into 35,866 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis) in connection with the closing of the IPO.
F16 Represents a right to purchase an aggregate of 123,811 shares of Common Stock underlying 10 warrants at an exercise price of $5.25 per share, all of which were issued to Mr. Girgenti on July 20, 2022.
F17 The Series A Convertible Preferred Stock has no expiration date but will automatically convert into fully paid and nonassessable shares of Common Stock at the then-effective conversion rate of the Series A Preferred Stock, which is initially 1-for-7 but is subject to further adjustment in the event of a stock split, stock dividend, or similar event.
F18 Represents a right to purchase 64,848 shares of Common Stock upon exercise of a ten-year option granted to Mr. Girgenti under the Issuer's 2014 Equity Incentive Plan (the "EIP") on April 28, 2014. This option vested in 7 monthly installments beginning on April 28, 2014 and is fully vested and exercisable as of the date of this report.
F19 Represents a right to purchase 3,571 shares of Common Stock upon exercise of a ten-year option granted to Mr. Girgenti under the EIP on July 27, 2015. This option vested in 12 monthly installments beginning on July 27, 2015 and is fully vested and exercisable as of the date of this report.
F20 Represents a right to purchase 3,571 shares of Common Stock upon exercise of a ten-year option granted to Mr. Girgenti under the EIP on July 25, 2016. This option vested in 12 monthly installments beginning on July 25, 2016 and is fully vested and exercisable as of the date of this report.
F21 Represents a right to purchase 3,571 shares of Common Stock upon exercise of a ten-year option granted to Mr. Girgenti under the EIP on April 24, 2017. This option vested in 12 monthly installments beginning on April 24, 2017 and is fully vested and exercisable as of the date of this report.
F22 Represents a right to purchase 7,142 shares of Common Stock upon exercise of a ten-year option granted to Mr. Girgenti under the EIP on May 7, 2018. This option vested in 12 monthly installments beginning on May 7, 2018 and is fully vested and exercisable as of the date of this report.
F23 Represents a right to purchase 7,142 shares of Common Stock upon exercise of a ten-year option granted to Mr. Girgenti under the EIP on July 29, 2019. This option vested in 12 monthly installments beginning on July 29, 2019 and is fully vested and exercisable as of the date of this report.
F24 Represents a right to purchase 7,142 shares of Common Stock upon exercise of a ten-year option granted to Mr. Girgenti under the EIP on July 27, 2020. This option vested in 12 monthly installments beginning on July 27, 2020 and is fully vested and exercisable as of the date of this report.
F25 Represents a right to purchase 7,142 shares of Common Stock upon exercise of a ten-year option granted to Mr. Girgenti under the EIP on December 16, 2021. This option vested in 12 monthly installments beginning on December 16, 2021 and is fully vested and exercisable as of the date of this report.

Remarks:

Exhibit 24.1: Power of Attorney (Steven Girgenti)